Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Maria Antonieta Moraes, Instituto de Cardiologia do Rio Grande do Sul

ClinicalTrials.gov Identifier:

NCT01545479

First received: January 16, 2012

Last updated: March 1, 2012

Last verified: March 2012

History of Changes

Purpose

It is well established that renal hypoxia is associated with the development of renal injury. The purpose of this study is measure the alterations in renal blood oxygenation after angiotensin II converting enzyme inhibition. The understanding of kidney adaptive mechanisms to renin angiotensin system effects in healthy subjects will be useful for the early detection of renal disease and for the development of new therapies to decrease the progression of the disease and its consequences.

Condition	Intervention	Phase
Renal Disease	Drug: captopril 25mg	Phase 4

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Health Services Research
Official Title:	Renal Oxygen Content is Increased in Healthy Subjects After Angiotensin Converting Enzyme Inhibition

Resource links provided by NLM:

Drug Information available for: Captopril

U.S. FDA Resources

Further study details as provided by Instituto de Cardiologia do Rio Grande do Sul:

Primary Outcome Measures:

Measure the renal blood oxigenation after angiotensin converting enzyme inhibition [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]

Enrollment:	5
Study Start Date:	January 2010
Study Completion Date:	December 2010
Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Captopril 25mg To study the renal blood oxygenation, the subjects took captopril (25mg).	Drug: captopril 25mg renal blood oxygenation after captopril Other Name: BOLD-MRI

Show Detailed Description

Eligibility

Ages Eligible for Study:	45 Years to 55 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy female between 45 and 55 years

Exclusion Criteria

man and
health female below 45 and above 55 years

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01545479

Sponsors and Collaborators

Instituto de Cardiologia do Rio Grande do Sul

Investigators

Study Chair:

MAntonieta Moraes, Dr

Instituto de Cardiologia do Rio Grande do Sul

More Information

No publications provided by Instituto de Cardiologia do Rio Grande do Sul

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Stein A, Goldmeier S, Voltolini S, Setogutti E, Feldman C, Figueiredo E, Eick R, Irigoyen M, Rigatto K. Renal oxygen content is increased in healthy subjects after angiotensin-converting enzyme inhibition. Clinics (Sao Paulo). 2012 Jul;67(7):761-5.

Responsible Party:	Maria Antonieta Moraes, Doctorate, Instituto de Cardiologia do Rio Grande do Sul
ClinicalTrials.gov Identifier:	NCT01545479 History of Changes
Other Study ID Numbers:	4111/08
Study First Received:	January 16, 2012
Last Updated:	March 1, 2012
Health Authority:	Brazil: Ethics Committee

Keywords provided by Instituto de Cardiologia do Rio Grande do Sul:

ECA
BOLD-MRI
kidney

Additional relevant MeSH terms:

Kidney Diseases
Urologic Diseases
Captopril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 19, 2013

To Top